317 Safety and efficacy results from a phase 1 dose-escalation trial of the parp inhibitor talazoparib (bmn-673) in combination with either temozolomide or irinotecan in patients with advanced malignancies. (September 2015) - Wainberg, Z.A.; Hecht, J.R.; Konecny, G.E.; Chmielowski, B.; Finn, R.S.; Martinez, D.; Yonemoto, L.; Glaspy, J.; Slamon, D.J.